- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2020
- EULAR 2019
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2020
- ACR 2019
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2019
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- Bilddatenbank
- RheumaTool
- SlideSet RA
- SlideSetSpA
- SonoTool
- FOCUS «Der Fuss»
- FOCUS «Die Hand»
- FOCUS «Kinderrheuma»
- EisenPaket
- LupusPaket
- OsteoPaket
- Publikationen
- Literaturservice
- Richtlinien
- Schmerzpaket
- Immunotalk
ACR 2020 | Daily Highlights
Herpes zoster under Anifrolumab
HERPES ZOSTER EVENTS WITH ANIFROLUMAB IN PATIENTS WITH ACTIVE SLE: AN INTEGRATED ANALYSIS OF PHASE 2 AND PHASE 3 TRIALS
Abstract: 0849
Authors: J. Merrill al.
Key content:
Treatment with anifrolumab, a monoclonal antibody to the type I interferon receptor, was associated with clinical benefit in one phase 2 and two phase 3 trials of patients with SLE. Herpes zoster occurred in 5.4% (n=5), 6.1% (n=28), and 8.6% (n=9) of patients in the anifrolumab 150-mg, 300-mg, and 1000-mg groups, respectively, compared with 1.3% in the pooled placebo group. Herpes zoster rates were more frequent with concomitant immunosuppressants. Duration and severity were comparable between treatment groups, and most herpes zoster events were mild to moderate, cutaneous, and resolved without discontinuation of anifrolumab.d a higher prevalence of dry eyes and a lower prevalence of long standing lymphadenopathy (2.7% vs 19.5%) and lymphoma (0% vs 15%).
Relevance:
In line with the importance of type I interferon in antiviral defense, this analysis indicates an elevated risk of herpes zoster with anifrolumab, an antibody that will likely enrich our therapeutic armamentarium against SLE.
Zusammenfassung und Kommentar von:
Prof. Dr. Ulrich Walker
Basel
